about
Update on the treatment of ankylosing spondylitis.Current and emerging strategies for the management of sarcoidosis.Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanerceptDrug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesLong-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.Pulmonary complications of tumor necrosis factor-targeted therapy.Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature.Coexistence of Ankylosing Spondylitis and Löfgren's Syndrome.Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders.Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature.New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication.Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Etanercept for treating axial spondyloarthritis.Etanercept for the treatment of non-radiographic axial spondyloarthritis.Certolizumab Pegol-Induced Folliculitis-Like Lichenoid Sarcoidosis in a Patient with Rheumatoid Arthritis.Update on bioagent therapy in sarcoidosis.Alpha-interferon induced sarcoidosis mimicking metastatic melanoma.Pulmonary sarcoidosis associated with etanercept therapy.Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?Sarcoidosis and spondyloarthritis: A coincidence or common etiopathogenesis?A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis
P2860
Q34592673-81A2DBAE-4BA1-4585-983B-DC87F852682EQ34636680-941D5D85-2455-412A-82D8-76356E038DF3Q34768871-859B4331-285E-442A-BCA1-FB96BA886214Q35852535-7227151C-E65A-4182-BAA5-72213F729C9FQ36724093-1F668C53-5077-4B62-9995-7317C7825210Q37215981-F8681C6A-4CA2-4D9B-8B73-067BC3FDAFFDQ37345155-F3598DCA-65A0-48A9-B646-0C5F433B5F9DQ37474072-C080F885-D957-4B51-9882-78081DCDC571Q37654068-1EA81F84-0247-4FB2-AE0B-B1B2A8294BA9Q37679545-CAC88FF8-58CC-4E12-9CA0-73F9D1CFBF87Q37754686-1A505D61-36D4-49EB-B02D-E58582F63DFEQ37802768-1EB0DFD8-2540-4390-865B-A8CA7C1E12A3Q37990516-733E1FCD-CE7A-4F18-8219-63DB64FBFCD7Q38060268-3441D77C-15B8-436B-93C4-82996FE879C9Q38099248-5EBDC00B-324B-4503-A8C8-000C05DB42A2Q38691419-1D0C8571-1D66-4164-AED9-4BDEFE7983E7Q38703849-A40A5812-76F1-4AA0-92C8-68A4D83FC9E5Q42375001-2435486D-338A-4C1F-A6F9-0CC9B428717BQ42415512-FD8CBD0E-250D-4FBE-AEED-F29CFFB6F04AQ46083532-DD46A960-0FEB-46B2-A540-AAD1AE7339EBQ46981061-75CD81AC-1530-4246-A691-E10940BB2F12Q48009777-E298ADC0-E661-47ED-B340-61C0BB7527D4Q49708142-E46226F0-12C0-499E-B303-1F277C408A8BQ58133983-056750F6-D2C0-46E0-9229-9BD94C250CFD
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Development of sarcoidosis during etanercept therapy.
@en
type
label
Development of sarcoidosis during etanercept therapy.
@en
prefLabel
Development of sarcoidosis during etanercept therapy.
@en
P2093
P356
P1476
Development of sarcoidosis during etanercept therapy.
@en
P2093
Héctor Fernández-Llaca
M Carmen González-Vela
Marcos A González-López
Ricardo Blanco
Vicente Rodríguez-Valverde
P304
P356
10.1002/ART.22238
P577
2006-10-01T00:00:00Z